Yazar "Tombuloglu, Murat" seçeneğine göre listele
Listeleniyor 1 - 20 / 58
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe add(12)(q24) and trisomy 14 acquired during clonal evolution in a patient with atypical myeloproliferative disorder harboring t(8;13)(p12;q12)(Springer, 2007) Sahin, Fahri; Ay, Ertan; Yuksel, Erdinc; Ertan, Yesim; Ocakci, Serkan; Tombuloglu, Murat; Saydam, Güray; Sercan, ZeynepÖğe Allogeneic Heamatopoietic Stem Cell Transplantation in Elderly Patients; Single Centre Experience(Nature Publishing Group, 2018) Bulbul, Hale; Atilla, Fatos Dilan; Soyer, Nur Akad; Tombuloglu, Murat; Tobu, Mahmut; Sahin, Fahri; Vural, Filiz[No Abstract Available]Öğe Allogeneic hematopoietic stem cell transplantation in adult aplastic anaemia patients: Promising treatment modality(Nature Publishing Group, 2019) Davulcu, Eren Arslan; Bulbul, Hale; Ulusoy, Yusuf; Soyer, Nur Akad; Karadag, Fatma Keklik; Arslan, Aysenur; Sahin, Fahri; Tobu, Mahmut; Saydam, Güray; Tombuloglu, Murat; Vural, FilizÖğe Amyloid deposition in knee and ankle joints in the course of multiple myeloma(Elsevier France-Editions Scientifiques Medicales Elsevier, 2007) Sahin, Fahri; Soyer, Nur Akad; Saydam, Güray; Vural, Filiz; Tombuloglu, Murat; Argin, Mehmet; Ertan, YesimÖğe ANALYSIS OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES UNDERGONE STEM CELL TRANSPLANTATION UNDER VORICONAZOLE PROPHYLAXIS(Nature Publishing Group, 2018) Davulcu, Eren Arslan; Soyer, Nur; Tombuloglu, Murat; Tobu, Mahmut; Saydam, Guray; Sahin, Fahri; Vural, Filiz[No Abstract Available]Öğe Assessment of haematology patients with confirmed H1N1 positivity(Tubitak Scientific & Technical Research Council Turkey, 2012) Ozdemirkiran, Fusun; Pullukcu, Husnu; Cicek, Candan; Cagirgan, Seckin; Tombuloglu, Murat; Vural, Filiz; Saydam, GürayAim: H1N1 influenza virus infections in immunosuppressive patients cause complications. Clinical and laboratory findings of H1N1 positive haematology patients were evaluated in this study. Materials and methods: The "H1N1 Swine Influenza Suspicious Case Notification Form and Inpatient Follow-up Form" was prepared for 15 patients with suspected H1N1 infection between October 2009 and May 2010. H1N1 was detected by real-time RT-PCR assay. For all cases medical records were reviewed for clinical, demographic, and haematologic information. Results: H1N1 positivity was confirmed using real-time RT-PCR in 9 out of 15 patients (11 men, 4 women). One of the 9 patients had been followed up due to aplastic anaemia, 1 due to Evans syndrome, and the remaining 7 due to haematologic malignancy. Among the 9 patients diagnosed with H1N1,3 had previously undergone autologous haemopoietic stem cell transplantation (HSCT). H1N1 was detected in HSCT recipients in the early post-transplant period (range 7-21 days). The most prominent symptoms were as follows: high fever, cough, vomiting, nausea, and diarrhoea, in descending order. Oseltamivir was given to all patients. Eight patients responded to the treatment and recovered clinically. One patient (57-year-old female with multiple myeloma), required intensive care and she died due to severe sepsis and pneumonia. Conclusion: Our data show that subjective findings like headache and fatigue often seen in influenza infections were not the dominant clinical presentation in these patients. These infections should be considered in patients with haematological malignancy, and appropriate treatment and prophylaxis should be started early.Öğe Bilateral Sixth Nerve Palsies Possibly Associated with Arsenic Trioxide in Acute Promyelocytic Leukaemia(Akad Doktorlar Yayinevi, 2016) Patir, Pusem; Oytun, Merve; Ozluk, Ahmet A.; Saydam, Güray; Donmez, Ayhan; Tombuloglu, MuratÖğe Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience(Tubitak Scientific & Technical Research Council Turkey, 2018) Uysal, Ayse; Akad Soyer, Nur; Ozkan, Melda; Sahin, Fahri; Vural, Filiz; Tobu, Mahmut; Tombuloglu, Murat; Saydam, GürayBackground/aim: Carfilzomib (CFZ) is a new-generation proteasome inhibitor with significant activity in relapsed or refractory multiple myeloma (R/R-MM). We have retrospectively evaluated R/R-MM patients who were treated with CFZ plus dexamethasone. Materials and methods: Twenty-one R/R-MM patients who were treated with CFZ plus dexamethasone between October 2013 and January 2016 were screened. The patients were followed until March 2016 after CFZ treatment. Results: Ten (47.6%) of the patients were female and 11 (52.4%) of them were male. The median age was 62 (47-76) years. The median number of prior treatment lines was 3 (2-7). The median number of administered cycles of treatment for CFZ was 4 (1-10). The median overall response rate was 26.3%. The most common hematological adverse events were anemia and thrombocytopenia (38%). The most common nonhematological adverse event was fatigue (71.4%). One patient died because of a cerebrovascular event and 1 patient died because of pneumonia during the treatment period. The median duration of response rate and time to next therapy were 8 (7-9) and 3 (2-16) months, respectively. The median overall survival was 8 (0.5-33) months. Conclusion: Despite the small number of patients, our results suggest that CFZ provides acceptable responses in heavily pretreated R/R-MM patients.Öğe CD31 expression on peripheral blood stem cells predicts both early neutrophil and platelet engraftments(Pergamon-Elsevier Science Ltd, 2013) Donmez, Ayhan; Tombuloglu, Murat; Gulbahar, Okan; Arik, Bahar; Cagirgan, Seckin; Vural, Filiz; Gokmen, NihalNo detailed information currently exists about the immune phenotypic profiles of peripheral blood stem cells (PBSCs) obtained by different mobilization regimens. The effects of these profiles on the outcome of transplantation are largely unknown. In this prospective study, the surface immune phenotypic features (CD11a, CD18, CD31, CD38, CD44, CD62e, CD62L, CD90, CD117, CD135 and CD184 expression) of sorted PBSCs that had been mobilized by growth factor with (group I and group II) or without (group III) disease-specific chemotherapies were investigated. The immune phenotypic features on mobilized PBSCs in groups I, II and III were not significantly different. The CD31 (platelet endothelial cell adhesion molecule-1) positivity ratio on PBSCs inversely correlated with both the duration of neutrophil (r = -0.32, p = 0.03) and platelet (r = -0.36, p = 0.02) engraftment. No relationship was found between the engraftment (neutrophil and platelet) durations and CD184 (chemokine receptor CXC motif receptor 4 [CXCR4]) expression on PBSCs. We demonstrated that the surface immune phenotypic profiles on PBSCs obtained by several mobilization regimens were not different. To our knowledge, this is the first study to demonstrate that CD31 expression on human PBSCs may positively affect both neutrophil and platelet engraftment. Contrary to our expectations, CD184 (CXCR4) expression on PBSCs has no effect on neutrophil or platelet engraftment. Considered together, our results suggest that additional surface antigens (such as CD31) may be more effective in the homing process. (C) 2013 Elsevier Ltd. All rights reserved.Öğe Celiac disease associated with B-cell lymphoma(Aves, 2010) Oruc, Nevin; Ozutemiz, Omer; Tekin, Fatih; Sezak, Murat; Tuncyurek, Muge; Krasinskas, Alyssa M.; Tombuloglu, MuratCeliac disease is a gluten-induced enteropathy controlled by gluten restriction. Celiac disease is occasionally associated with T-cell lymphoma. We report a case with celiac disease who presented with duodenal ulcer-like symptoms and endoscopic findings. The persistent symptoms despite a strict diet led to the suspicion of an associated malignancy. Intensive evaluation revealed a case with celiac disease associated with B-cell lymphoma. Although B-cell lymphoma is rare, it should be kept in mind especially in female patients with persistent symptoms and refractory celiac disease.Öğe Cholesterol Levels in Patients with Chronic Lymphocytic Leukemia(Natl Med Assoc, 2017) Yavasoglu, Irfan; Sargin, Gokhan; Yilmaz, Fergun; Altindag, Sermin; Akgun, Gulsum; Tombak, Anil; Toka, Bila; Dal, Sinan; Ozbas, Hasan; Cetin, Guven; Donmez, Ayhan; Yegin, Zeynep Arzu; Bilgir, Oktay; Tiftik, Naci; Ertop, Sehmus; Ayyildiz, Orhan; Sonmez, Mehmet; Pektas, Gokhan; Kadikoylu, Gurhan; Tombuloglu, Murat; Bolaman, ZahitLow cholesterol levels may be accompanied by solid tumors or hematological malignancies such as multiple myeloma. Decreased cholesterol levels have been reported in some experimental studies about chronic lymphocytic leukemia (CLL). It may be associated with tumoral cell metabolism. Herein, we examine blood lipid profiles of patients with newly diagnosed CLL (284 male, 276 female, mean age 64 +/- 11 years) as defined by National Cancer Institute criteria. The control group consisted of 71 healthy subjects with mean age 55 +/- 9 years (28 male, 43 females). 60% of patients with Binet A, while 25% were Binet C. Decreased levels of total cholesterol, high density lipoprotein (HDL) and low density lipoprotein (LDL) were observed in patients with CLL than control group (p < 0,001). There was no statistical significance between CLL and control group for triglycerides (TG) and very low density lipoprotein (VLDL), also between HDL-C, VLDL, TG and grades. Cholesterol may metabolized by abnormal lymphocytes in CLL patients.Öğe Cholesterol levels in patients with multiple myeloma(Springer, 2008) Yavasoglu, Irfan; Tombuloglu, Murat; Kadikoylu, Gurhan; Donmez, Ayhan; Cagirgan, Seckin; Bolaman, ZahitHypocholesterolemia is seen in solid tumors and some hematological malignancies. We assessed cholesterol levels and the relationship between these levels and types and stages of multiple myeloma (MM) in the patients with MM. One-hundred two patients (60 male and 42 female) of mean age 59 +/- 11 years with MM were enrolled to this study. While 71.6% of the patients were Ig G type, 80.4% of the patients were at stage III. In the control group, there were 71 healthy persons (42 male and 29 female) of mean age 58 +/- 8 years. The levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) in the patients with MM were significantly lower than the controls (p<0.001). There was no difference for the levels of very-low-density lipoprotein cholesterol and triglyceride between the two groups (p>0.05). Lipid parameters were not different between Ig types (p>0.05). The levels of TC and LDL-C in the patients with stage I were higher than those of stages II and III (p<0.001 and p<0.005, respectively). The levels of TC and LDL-C in the controls were not higher than the patients with stage I (p>0.05). HDL-C levels in the patients with stage III were lower than controls (p<0.001). Hypocholesterolemia are seen in the patients with MM. Hypocholesterolemia may be due to increased LDL clearance and utilization of cholesterol by myeloma cells.Öğe Chronic myelogenous leukemia exhibiting trisomy 14 due to a Robertsonian translocation with philadelphia chromosome(Informa Healthcare, 2008) Durmaz, Burak; Karaca, Emin; Vural, Filiz; Cogulu, Ozgur; Alpman, Asude; Tombuloglu, Murat; Özkınay, FerdaÖğe The clearance time of infused hematopoietic stem cell from the blood circulation(Pergamon-Elsevier Science Ltd, 2013) Donmez, Ayhan; Ozsan, Fatma; Arik, Bahar; Ozkayin, Nese; Cagirgan, Seckin; Mir, Sevgi; Vural, Filiz; Tombuloglu, MuratThere is no detailed information about the clearance time of infused hematopoietic stem cell (HSC) from the blood circulation in humans. In this prospective study, peripheral blood CD34+ cell counts were detected during the 4 days period following autologous HSC transplantation in 20 patients by means of flow cytometry. The median CD34+ cells were at the highest level in the first hour and decreased below pre-infusion values on the first day after HSC infusion. By nonparametric analysis, positive correlation was found between CD34+ cell levels at the first hour and the post-thaw CD34+ cell dose (r = 0.57, p = 0.01). An inverse correlation was determined between CD34+ cell levels at the first hour and neutrophil engraftment (r = -0.54, p = 0.01). Compared with the patients having CD34+ cell count of >= 2 mu L-1 in the first hour following HSC infusion, the patients having CD34+ cell count of <2 mu L-1 had delayed both neutrophil (20 vs. 12, p = 0.008) and platelet (47 vs. 11, p = 0.01) engraftments. Our results indicated that infused HSCs were removed from the blood circulation within 1 day. In addition, CD34+ cell levels at the first hour may be used as an important indicator to predict the delay of neutrophil and platelet engraftments. (c) 2013 Elsevier Ltd. All rights reserved.Öğe Clinical side effects during peripheral blood progenitor cell infusion(Pergamon-Elsevier Science Ltd, 2007) Donmez, Ayhan; Tombuloglu, Murat; Gungor, Ayse; Soyer, Nur; Saydam, Güray; Cagirgan, SeckinThere are several side effects which have been reported during the infusion of peripheral blood progenitor cells (PBPCs) either due to the infusion or the content of the infusate. We have evaluated the side effects detected during PBPCs infusion in 194 autologous and 25 allogeneic transplantations. In autologous cryopreserved PBPCs infusion, we detected a total of forty-nine (25.25%) side effect events during and after the infusion period. Forty-six (23.71%) of these side effects were detected during the infusion period including fifteen (7.73%) cardiac side effects, which required stopping the infusion, and thirty-one (15.97%) non-cardiac side effects, which did not require cessation of the infusion. Sinus bradycardia after a minimum of 45 min after completing the infusion was seen in three (1.54'%) patients. The median volume, dimethyl sulfoxide (DMSO) and total nucleated cell (TNC) content of the product were found to be significantly higher in patients with side effects compared to the group without any side effects (P < 0.05). The median volume and DMSO content were found to be significantly higher in patients with cardiac side effects compared to non-cardiac side effects (P < 0.05). There was no cardiac side effects in patients treated with an infusate containing 100 x 10(9) L-1 leukocytes. We did not observe any infusion-related side effects in patients given allogeneic non-cryopreserved PBPCs. We have concluded that the volume, DMSO and TNC content of autologous cryopreserved PBPCs product are directly related to clinical side effects. (c) 2006 Elsevier Ltd. All rights reserved.Öğe Combined treatment for severe steroid-refractory acute graft-versus-host disease in acute promyelocytic leukemia case on its third allogeneic hematopoietic stem cell transplantation(Nature Publishing Group, 2018) Atilla, Fatos Dilan; Soyer, Nur; Donmez, Ayhan; Tombuloglu, Murat[No Abstract Available]Öğe Comparison of CD38, ZAP70 and hTERT Expression with Known Prognostic Markers in Patients with Chronic Lymphocytic Leukemia During Five-Year Follow- up Period(Akad Doktorlar Yayinevi, 2014) Vural, Filiz; Karaca, Emin; Soyer, Nur; Gunduz, Cumhur; Sahin, Fahri; Kosova, Buket; Saydam, Güray; Cagirgan, Seckin; Tombuloglu, Murat; Özkınay, Ferda; Cogulu, OzgurChronic Lymphocytic Leukemia (CLL) is the most common leukemia in adults. Recently CD38, ZAP70 and hTERT activity have been studied for the evaluation of the prognosis of CLL besides clinical staging and lymphocyte doubling time. There are inconsistent results regarding these markers for the evaluation of the prognosis in CLL patients. In this study CD38, ZAP70 and hTERT values in CLL patients were measured to make comparisons between each other and known prognostic factors. Thirty CLL patients who were included in the study were followed up for 5 years after the initial diagnosis. The mean hTERT value in CLL and control cases were 1.00 +/- 1.31 and 3.89 +/- 3.58, respectively (p< 0.05). The mean CD38 and ZAP70 were 6.20 +/- 7.60 and 5.51 +/- 5.67, respectively. No significant association was detected between CD38, ZAP70 and hTERT activity. There was no correlation between those parameters and known prognostic parameters such as Rai staging, peripheral lymphocyte levels, age, and sex of the patients, beta-2 microglobulin and reply to treatment in CLL. The overall five-year survival rate in CLL patients is 96.7%. The overall five-year survival rate in CLL patients is 96.7%. In conclusion, further studies including larger series of patients with longer follow-up periods are recommended.Öğe Cutaneous graft-versus-host disease after hematopoietic stem cell transplantation; a single institution experience(Nature Publishing Group, 2018) Atilla, Fatos Dilan; Bulbul, Hale; Soyer, Nur; Turk, Bengu Gerceker; Acar, Ayda; Tombuloglu, Murat; Vural, Filiz[No Abstract Available]Öğe CYTOMEGALOVIRUS INFECTION IN ALLOGENEIC HEMATOPOIETIC CTEM CELL TRANSPLANT PATIENTS WITH HEMATOLOGICAL DISEASES: A SINGLE CENTER EXPERIENCE(Nature Publishing Group, 2018) Davulcu, Eren Arslan; Soyer, Nur; Sahin, Fahri; Saydam, Guray; Tombuloglu, Murat; Tobu, Mahmut; Vural, Filiz[No Abstract Available]Öğe Determining Toxoplasma high-risk autologous and allogeneic hematopoietic stem cell transplantation patients by systematic pre-transplant PCR screening of stem cell originated buffy coat(Elsevier Ireland Ltd, 2012) Caner, Ayse; Donmez, Ayhan; Doskaya, Mert; Degirmenci, Aysu; Tombuloglu, Murat; Cagirgan, Seckin; Guy, Edward; Francis, Janet; Soyer, Nur Akad; Guruz, YukselThe diagnosis of Toxoplasma infection or disease in hematopoietic stem cell transplantation (HSCT) patients is achieved mainly by PCR screening; however screening did not find wide field of use in practice due to costly expenditures of PCR. This study aimed to determine patients at high risk of Toxoplasma infection or disease before transplantation by stem cell originated buffy coat PCR and subsequently to screen them. Buffy coats collected from 12 autologous and 18 allogeneic HSCF patients' donors were investigated by PCR before transplantation. After transplantation, blood and sera collected at fixed time intervals were screened by two PCR methods and serological assays. Screening results first time assessed a toxoplasmosis incidence level as 25% in autologous HSCT patients and increased incidence level in allogeneic HSCT patients to 22%. Importantly, huffy coat PCR was first time performed before transplantation, to determine the risk of toxoplasmosis. Buffy coat PCR results showed that four patients were at high risk of toxoplasmosis before transplantation. After transplantation, these patients experienced toxoplasmosis. In conclusion, for the determination of patients at risk of toxoplasmosis, clinicians should consider buffy coat PCR in combination with serology before transplantation. After transplantation, PCR screening can be initiated in high risk patients upon clinical suspicion. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
- «
- 1 (current)
- 2
- 3
- »
